While biotech and other specialized technology companies are being called upon to handle early stage work such as target identification and validation, early toxicology or high throughput screening, as a recent article in Forbes [Universities Stepping Up Efforts To Discover Drugs] indicates, universities are also being brought to the table in increasing fashion.
Merck joins a number of companies including Pfizer, Lilly, AstraZeneca, etc., who have reasoned that decreasing sales due to patent expirations necessitates “right sizing” its internal R&D operations.
Pharmaceutical companies looking to reduce their internal R&D spending and universities needing to maximize their limited budgets and improve their success bodes well for companies like ours. Through collaboration and leveraging our proprietary drug discovery technology platform, CHEMSAS®, we can reduce the time and cost of drug discovery while improving the probability of clinical & commercial success. In pharmaceutical drug development, speed is only useful if it comes with accuracy – CHEMSAS® delivers both.